Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular Carcinoma

Inclusion Criteria

• Targeted therapy is acceptable within 1-2 months after liver transplantation.

• Immunosuppressive regimen consists of calcineurin inhibitor, mycophenolate mofetil and sirolimus.

• All male and female participants must take reliable contraceptive measures during the trial and within four weeks after the end of the trial.

• The definition of high-risk patients:

• The PET scan is positive before LDLT;

• Tumors beyond USCF criteria

• Poorly-differentiated tumor;

• The patients who has poor AFP response (<15%)or AFP>400 ng/ml after LRT after conventional LRT (RFA、PEI or TACE)

Exclusion Criteria

• Life expectancy is less than 3 months

• Patients are with other malignant tumors simultaneously.

• Patients are anaphylaxis to the inactive ingredients of lenvatinib or drugs.

• Pregnant or lactating women (Female participants need pregnancy test within 7 days before treatment).

• Preoperative history of severe cardiovascular disease: congestive heart failure > NYHA grade 2; active coronary heart disease (myocardial infarction occurred within 6 months before entry into the study); severe arrhythmia requiring antiarrhythmic treatment (allowable use of beta-blockers or digoxin); uncontrolled hypertension.

• History of HIV infection.

• Severe clinical active infections (> NCI-CTCAE version 3.0).

• Epilepsy patients requires medication (e.g. steroids or antiepileptic drugs).

• Patients with kidney diseases requires renal dialysis.

• Drug abuse, medical symptoms, mental illness or social status that may interfere with participants' participation in research or evaluation of research results.

• Patients who could not swallow oral drugs, such as those with severe upper gastrointestinal obstruction and need gastric tube feeding.